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Rationale: To improve COPD management in primary care, it is first necessary to describe these 
patients using clinically-relevant variables that can be collected practically and monitored 
longitudinally. Our aim was to describe the demographic and clinical characteristics of COPD patients 
managed in U.S. primary care.  
Methods: This is an observational, patient registry study using data from the COPD Optimum Patient 
care DARTNet Research Database (COPD-RD) from which the Advancing the Patient Experience (APEX) 
COPD registry is derived. The APEX in COPD registry is the first U.S. primary care, based registry, to 
collect both retrospective and prospective electronic health record (EHR) data and patient reported 
information/outcomes and plans to include 3,000 COPD patients. COPD patients included in the 
registry were aged ≥35 years at diagnosis with a COPD diagnosis code [ICD9CM, ICD10CM]. Baseline 
demographic and clinical EHR data for all available patients were accessed (Dec 2019-Jan 2020) from 
5 U.S. large primary care medical groups  located in TX, CO, NC, OH and NY. Most data extend back as 
far as 2009.  
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Results: Baseline data from 17,192 available patients (mean age (SD): 67.4 years (11.3)) were included. 
Patients were predominantly female (n=9,689/17,192; 56.4%), white (n=9,732/15,216; 56.6%), 
current- (n=6,428/17,192; 37.4%) and ex-smokers (n=7,356/17,192; 42.8%) and over-weight/obese 
(n=8,620/12,475; 69.1% ). Overall, 38.3% of patients (n=6,579/17,192) experienced ≥1 exacerbation 
(acute lower respiratory event) in the last 12 months; 22.3%, 8.4% and 7.6% experienced 1, 2 and ≥3 
exacerbations, respectively. Of those patients with a blood eosinophil count (BEC) reading 
(n=8,882/17,192; 51.7%) most had a BEC (ever) in the range 150-300 cells/µL (n=4,062/8,882; 45.7%) 
and >300 cells/µL (n=3,102/8,882; 34.9%). Overall, 2.9% of patients (n=494/17,192) received no 
therapy (last 12 months), 9.2%  (n=1,587/17,192) were on short-acting bronchodilators only, 12.4% 
(n=2,127/17,192) were on LAMA,  13.2% (n=2,265/17,192) on LABA/LAMA, 5.7% (n=979/17,192) on 
ICS monotherapy, 28.9% (n=4,970/17,192) on ICS/LABA and 27.1% (n=4,658/17,192) on 
ICS/LAMA/LABA therapy. The most common comorbidities were hypertension (n=12,488/17,192; 
72.6%), diabetes mellitus (7,724/17,192; 44.9%), depression (n=7,240/17,192; 42.1%), osteoarthritis 
(n=7,098/17,192; 41.3%), anxiety (n=5,403/17,192; 31.4%), obstructive sleep apnea (n=6,295/17,192; 
36.6%), GERD (n=6,758/17,192; 39.3%), and asthma (5,713/17,192; 33.2%).  
Conclusion: These data comprehensively describe patients diagnosed with COPD managed in U.S. 
primary care, emphasizing the high exacerbation and co-morbidity burden. Approximately 20% of 
patients coded as COPD are not treated with correct maintenance medication. 
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